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I. Abstract 
The plasmid p1471 was isolated from the ciprofloxacin (Cp) resistant Aeromonas hydrophila, medicinal 
leech isolate JG1471, which is a strain with a minimum inhibitory concentration (MIC) of > 32 µg/mL Cp. 
JG1471 carries a 6.8 Kb plasmid which contains Cp resistance gene qnrS2. qnrS2 is a plasmid mediated 
resistance gene that has been isolated from clinical and environmental sources and has been implicated 
in increased resistance to the fluoroquinolone (FQ) Cp. To determine the FQ resistance conferred by 
qnrS2, primers were designed to perform a Gibson Assembly to insert a 1.99 Kb fragment from pKAS46, 
containing an Escherichia coli origin of replication (R6K), multiple cloning sites (MCS) and a kanamycin 
(Km) resistance gene into the 6.8 Kb p1471. The R6K origin of replication allows successful plasmid 
replication in E. coli, while the Km resistance factors allow for selection of both Aeromonas and E. coli 
strains containing the construct. The presence of the MCS in the construct makes it possible for the 
plasmid to be used as a shuttle vector in future experiments. The assembled construct, pEL1, was 
transformed into the E. coli DH5α-λ pir strain. Several assays were then performed to confirm that the 
plasmid construct was assembled correctly. E. coli showed a marked increase in ciprofloxacin resistance 
upon addition of pEL1, with a ~8-fold increase in MIC from 0. 032 µg/mL to 0.25 µg/mL. When pEL1 was 
transformed into a CpS strain of Aeromonas veronii, the MIC showed a 3,000-fold increase, from 0.002 
µg/mL to 6 µg/mL, passing the 4 µg/mL clinical benchmark for resistance. This data suggests that the 
presence of qnrS2 in p1471, a high copy plasmid, may play a substantial role in the CpR of the strain. 
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II. Introduction  
Leeches have been used as medicinal tools since 200 BCE, though substantial changes have 
occurred in their prescribed use1. The European medicinal leech, Hirudo verbana, is no longer used to 
remove ‘evil spirits’ as it was in medieval times2. Instead, leech therapy employing H. verbana leeches is 
now a commonly used procedure for a broad spectrum of purposes that include application after 
reconstructive and plastic surgery such as digit replantation and graft transplants2. Leeches for 
hirudotherapy are purchased from Leeches USA, which is the only FDA-approved supplier of the 
medicinal leech for hirudotherapy. During and after hirudotherapy, venous congestion in the 
transplanted or reconstructed tissue wound site can present a real challenge to attaining successful 
outcome of the surgery. Venous blood return from the wound site dramatically decreases due to blood 
clotting and disruption of veins3. Leeches secrete vasodilators and anticoagulants like hirudin, which 
allow for improved blood flow to the surgically reconstructed sites and inhibit  the activity of thrombin, 
an enzyme with critical roles in coagulation of blood4. Several other proteins secreted by the leech allow 
for increased blood flow to the area and increased prevention of blood clotting so that venous 
congestion does not occur and the surgical area can continue to receive enough blood flow to eventually 
heal4. When post-operative venous congestion was observed in digit replantation performed by Dr. 
Tamai, he reported 17% salvage rate without any use of leeches5. When Dr. Iain Whitaker studied digit 
replantation with use of leeches, he observed a 70% salvage of the tissues6. A 77.98% salvage rate was 
observed as a result of leech therapy after reconstructive surgery in 277 cases overall3. Since physicians 
have begun to use hirudotherapy, tissue salvage has been substantially improved3.  
 While hirudotherapy is well established as a tool for tissue salvage in reconstructive surgery, this 
procedure is not without its risks; one consequence of hirudotherapy is an increased risk of infection. In 
some cases, infection as a result of leech therapy can lead to cellulitis, a simple bacterial infection of the 
skin. In more extreme cases, tissue loss and septicemia can occur as a result of infection, leading to 
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failure of the reconstruction or even death7. Without prophylactic antibiotic treatment, Whitaker 
observed a 26% infection rate of the reconstructed tissue after hirudotherapy. Upon addition of 
prophylactic treatment with antibiotics, however, Whitaker observed that the infection rate can go from 
26% to 12.5% of patients6. With the decreased infection rate comes an increased success rate of the 
surgical reconstruction6. 
 Infections following leech therapy are a result of the bacterial symbionts that reside in the gut of 
the medicinal leech. H. verbana has two main bacterial symbionts: Aeromonas species and Mucinivorans 
hirudinis,8. Aeromonas hydrophila is one of the Aeromonas species isolated from the gut of the leech, 
and is the primary isolate published in case reports describing infection with leech therapy. A. 
hydrophila is a member of the family Aeromonadaceae9. It is Gram-negative, rod shaped, motile, and a 
facultative anaerobe9. M. hirudinis is an anaerobic bacteria of the family Rikenellaceae that was isolated 
and cultivated on mucin-containing plates10.  
Symbiosis is a close association between two biological partners. In the case of H. verbana, it has 
been suggested that its symbionts provide the leech host with extra nutrients, such as acetate and B 
vitamins that the host is unable to produce by itself11,12. It has also been hypothesized that the gut 
symbionts play a role in prevention of pathogens in the blood meal from colonization of the gut of the 
leech13. On the other hand, the leech host provides the symbionts with nutrients and an environment 
for successful growth. Host-produced mucin is thought to allow Mucinivorans to proliferate8. Sialic acid 
utilization genes in Aeromonads allow them to digest and utilize the sialic acid provided by the host14. 
Certain genetic markers that allow Aeromonas to be pathogenic are utilized as colonization factors when 
Aeromonas is present in the leech. For example, the normally pathogenic Type II secretion system (T2SS) 
in Aeromonas species is necessary for colonization of the gut of the leech by the bacteria15. When the 
T2SS was inactivated by transposon mutagenesis, the Aeromonas strain was initially unable to colonize 
the gut of the leech15. The T2SS allows hemolysis of red blood cells in the blood meal, and when it is 
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knocked out, the mutant is unable to colonize this niche15. While these bacteria are beneficial symbionts 
in the leech gut, they can act as pathogens in other settings: the T2SS found in A. veronii has been 
implicated in pathogenicity and Aeromonas hydrophila, in particular, is the bacteria most commonly 
associated with wound infections following hirudotherapy15,7.  
 Standard procedure in clinical hirudotherapy includes prophylactic treatment with 
fluoroquinolones (FQs) such as ciprofloxacin (Cp) to prevent infection of the wound with Aeromonas 
species3. FQs are useful drugs when it comes to treatment of bacterial infections because they target 
the process of replication, reducing the ability of the bacteria to survive16. FQ’s enter the bacterial cell by 
passive diffusion (specifically through porins in the outer membrane in Gram-negative bacteria and 
through the lipid bilayer)17.  Once inside the cell, FQs bind to and inhibit the actions of topoisomerase 
proteins such as DNA gyrase (made up of protein subunits gyrA and gyrB) and topoisomerase IV 
(consisting of subunits parC and parE) which bind to the DNA to introduce supercoils that allow the DNA 
to be unwound downstream and then remove negative supercoils from the DNA when ATP is no longer 
present16.  FQ’s prevent DNA replication by direct interference in the replication process, with 
bactericidal effects on both Gram-negative and Gram-positive bacteria16. With the FQ bound to the 
enzyme, the supercoiling process will not continue and DNA cannot be replicated16 In Gram-negative 
bacteria, DNA gyrase is the primary FQ binding site, while topoisomerase IV is the main target in Gram-
positive bacteria18,16. In Gram-negative bacteria, FQ’s bind to DNA gyrase while it is bound to the DNA16. 
In Gram-positive bacteria, FQs bind to DNA type IV topoisomerase and produce bactericidal effects by 
binding to the DNA-topoisomerase complex while there is a  break in the DNA, just as it does with DNA 
gyrase, making FQs very useful antimicrobials16. 
 The enhanced bactericidal effects of the synthetic drug, Cp, against Gram-negative bacteria 
make it the treatment of choice for Aeromonas infections resulting from hirudotherapy. While there are 
multiple FQs on the market, Cp is meant for human use19.  Hirudotherapy is not the only route for 
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human acquisition of CpR bacterial infections. Resistance to enrofloxacin can also lead to CpR and human 
illness. In 2005, pharmaceutical companies withdrew enrofloxacin from use in poultry farms in the 
United States due to lack of FDA approval. Studies have shown that resistance to enrofloxacin developed 
in chickens treated for widespread infection of Campylobacter species20. Reports of FQ resistant 
Campylobacter bacteria associated with human consumption of infected poultry became more frequent. 
The patients acquired the resistant bacteria and experienced infection that could not be treated with 
clinically determined levels of ciprofloxacin21.  
Infections due to CpR Aeromonas bacteria, however, did not occur until 2011. Before 2011, 
prophylactic treatment of the patient with Cp was effective in prevention of infection. That year, 
however, Cp-resistant strains of Aeromonas hydrophila were isolated from wound infections following 
hirudotherapy, in some cases leading to tissue necrosis and loss of the reconstructed area22. When 
patients experience wound infections following hirudotherapy, the salvage rate of their tissue is 37.4%, 
while the tissue salvage rate is 88.3% when infection does not occur3. These statistics do not 
differentiate between patients who experience prophylactic treatment with Cp and those who don’t, 
but resistance to Cp, the commonly used prophylactic treatment, will likely continue to increase the rate 
of infection and subsequent tissue failure following hirudotherapy3. 
Cp resistance can be a result of several cellular changes. One of the first steps toward resistance 
is a mutation in the gyrA or parC subunits of DNA gyrase and topoisomerase IV, the two targets of Cp’s 
bactericidal mechanisms. When mutations occur in gyrA and parC, they primarily lead to amino acid 
changes in the active sites of the enzyme18. With a single point mutation in the quinolone resistance 
determining region (QRDR) of gyrA, resistance to ciprofloxacin can occur18. Bacteria with high-sensitivity 
DNA gyrase or topoisomerase IV enzymes have lower minimum inhibitory concentrations (MIC) of FQ’s, 
which is the concentration of antibacterial compound required to inhibit visible growth. These bacteria 
with highly sensitive enzymes have much lower MIC values than those with more Cp resistance, so it is 
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hypothesized that a mutation in both gyrA and parC that makes the replication enzymes less sensitive 
would lead to an even higher MIC than a single point mutation in either region would provide18.  FQ’s 
can diffuse into the cell through porins, so downregulation or mutations in porin proteins can contribute 
to resistance as well23. While chromosomal mutations and the resistance provided by the QRDR are 
important factors in Cp resistance, Cp resistance can also be increased as a result of plasmid-mediated 
resistance genes23.  
Plasmid-mediated factors are commonly found in CpR bacteria. One example of a plasmid-
mediated resistance factor is an efflux pump, a transmembrane pump that actively transports 
bactericidal compounds such as Cp out of the cell23. Genes encoding efflux pump proteins such as QepA 
and OqxAB are also thought to factor into Cp resistance. QepA provided a 32-fold increase in MIC of Cp 
when conjugated into E. coli23. QepA is a transmembrane protein that actively pumps out Cp from the 
cell23. QepA is just one of several plasmid-mediated resistance mechanisms. Another mechanism 
involves modification of Cp itself through a mutated aminoglycoside acetyl-transferase gene called 
aac(60)-Ib-cr, which acetylates and therefore deactivates Cp23. Observation of CpR strains of Aeromonas 
have shown an increase in MIC upon addition of more resistance factors24,25.  
One of the most recently determined plasmid-mediated resistance genes belongs in the qnr 
family23. The mechanism for FQ resistance as a result of Qnr proteins is not fully understood. One 
hypothesis is that the pentatpeptide repeat regions that make up Qnr act to destabilize the complex 
between Cp and DNA gyrase and allow DNA replication to occur23. The binding of Qnr proteins to DNA 
gyrase before it can bind to DNA allows prevention of FQs from binding the complex at all23. The specific 
gene qnrS2 has been found in both environmental samples and leech-associated A. hydrophila 
infections26. 
 Plasmid-mediated resistance factors are important for the spread of antibiotic resistance. 
Without the ability to transfer plasmids and plasmid-associated genes, qnr genes would not be so 
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widespread. Several qnr genes have been found in association with transposons that would allow them 
to be mobilized to different areas along the bacterial genome23. It has been hypothesized that qnrS 
genes are close to and potentially derived from qnr-like determinants from Vibrio splendidus27. Because 
Aeromonads are present in a variety of differing environments, further study could help determine if 
they are an important reservoir for the horizontal transmission of qnr genes27. While the mechanism by 
which qnr genes act may not be particularly well characterized at present, further research will provide 
more information about their role in FQ resistance as a whole. Table 2 shows a list of qnrS2 isolates in 
the scientific literature and the MIC values that the presence of the gene provides in Aeromonas, E. coli, 
and Salmonella isolates. 
 A. hydrophila is one of the species implicated in Cp-resistant wound infections. One strain, 
JG1471, was isolated from a leech shipped from Leeches USA, the only FDA-approved leech supplier in 
the United States. JG1471 has an MIC of >32 µg/mL likely due to both chromosomal and plasmid-
mediated mechanisms. JG1471 has point mutations in both gyrA and parC, as well as a plasmid-
mediated resistance mechanism within a 6.8 kb plasmid, p1471. The plasmid p1471 contains a qnrS2 
gene. It is likely that the chromosomal mutations give JG1471 an elevated Cp resistance, but that the 
plasmid-associated qnrS2 gene boosts CpR to high levels (>32 µg/mL) above typical therapeutic 
concentrations (1- 4 µg/mL Cp). Neither the mechanisms of qnrS2 nor the contribution to CpR is well 
characterized at present. A common approach to the study of different genes and their effects is to 
attach a gene of interest to a vector or other genetic tool that can allow expression of the gene in a new 
strain to observe phenotypic differences.  
One way to do this is to assemble a plasmid that ligates the gene of interest to a fragment that 
allows for replication and selection of the newly assembled plasmid. A Gibson Assembly (GA) is a 
procedure that is commonly used to accomplish this goal. It is a reaction that includes exonuclease, DNA 
polymerase, and DNA ligase activity in one buffer, making it a simple and effective strategy to introduce 
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new DNA sequences. Primers used for the GA must have an overhang where the two pieces of DNA can 
overlap for the purpose of ligation. The exonuclease chews back the 5’ ends of the DNA fragments, the 
fragments anneal where the primers overhang, DNA polymerase extends the 3’ ends, and DNA ligase 
seals the nicks to leave a fully assembled plasmid containing the original fragments. Figure 1 shows a 
diagram of how the GA works, while figure 2 shows the plasmids used for this research and the 
experimental plan for the GA. The newly assembled plasmid should have factors such as novel antibiotic 
resistance genes to provide selectivity, an origin of replication, and a multiple cloning site to allow future 
options for gene exploration. 
In order to explore the CpR coded by qnrS2, p1471 was isolated from JG1471 and ligated to a 
pKAS46 fragment to allow for replication in E. coli and its selection yielding pEL1. The goal was to 
combine p1471 with a pKAS46 fragment. The pKAS46 fragment contained an R6K origin of replication so 
that the plasmid could use an E. coli system to replicate, a kanamycin (Km) resistance gene to confer 
antibiotic resistance for selection of transformants, and a multiple cloning site (MCS) to allow for future 
use of the assembled plasmid as a shuttle vector in experiments.  
Upon transformation of the plasmid containing the resistance factors, pEL1, into E. coli and Cp 
susceptible (CpS) Hm21 Aeromonas veronii, the MIC of the recipient strain should rise substantially due 
to the presence of qnrS2 in the previously Cp susceptible (CpS) bacteria. If the pEL1 plasmid containing 
qnrS2 is transformed into gyrA and parC mutants of Hm21RS (a CpS strain of A. veronii), the MIC of the 
resultant cells should be higher than that of Hm21 A. veronii which does not contain any chromosomal 
mutations to increase CpR in the QRDR. The increased MIC of the two mutants with and without the 
presence of qnrS2 from pEL1 should provide a fuller picture of CpR in Aeromonas veronii as a whole. 
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 III. Methods 
3.1 JG1471 isolation and genome sequencing 
JG1471 was isolated from a Leeches USA shipment in February 2013 using a technique previously 
described28. Briefly, leeches were anaesthetized in 70% alcohol and a dorsal incision was made to 
withdraw intra-lumenal fluid (ILF) from the crop, a digestive compartment analogous to the stomach. 
The ILF was cultured on media containing Cp at a clinically high concentration of 6 g/mL from which 
JG1471 was isolated, subcultured, and frozen in glycerol stock for long-term storage. Genomic DNA was 
extracted using MasterPure™ DNA and RNA Purification Kit and the NexteraXT libraries were prepared 
for Illumina® MiSeq 2 x 250bp sequencing.  Reads were combined and assembled using CLC Genomics 
Workbench from Qiagen.  
3.2 Strains, growth and storage conditions 
All strains are kept in cryovials in a -80⁰C freezer. Aeromonas strains were incubated at 30⁰C and E. coli 
strains were incubated at 37⁰C. Strains used from the collection are listed below in Table 1.
 
Table 1: Strains used for the GA and transformation. CpR=Resistant to >32 µg/mL Cp, KmR=resistant to 
100 µg/mL kanamycin, CmR=resistant to 1µg/mL chloramphenicol 
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3.3 Media preparation 
LB broth was made by adding 10 g of BactoTM Tryptone (Becton, Dickinson and Co (BD) and Sparks, MD), 
5 g of BactoTM Yeast Extract (BD and Sparks, MD), and 10 g of NaCl into 1 L of distilled water, and 
autoclaved for 20 minutes at 121⁰C after which antibiotics were added when necessary. LB agar was 
made by addition of 1.5% BactoTM agar (BD and Sparks, MD) before sterilization. Blood agar for E-testing 
was prepared by the addition of 44 g of Columbia Blood Agar Base (Acumedia Inc. and Lansing, MI) to 1 L 
of dH2O and sterilization at 121⁰C for 20 minutes. Mueller Hinton agar for E-testing was prepared by 
addition of 38 g of Mueller HintonTM (BD and Sparks, MD) agar to 1 L of dH2O and sterilization. 
3.4 Growth curves 
Strain Hm21 and JG1471 from frozen stock were streaked for isolation on LB plates and LB with 4 µg/mL 
Cp plates, respectively, and grown 16 hours at 30⁰C. Overnight cultures were made with 5 mL of LB and 
4 µg/mL Cp and grown in 30⁰C shaker at 200 rpm for 16 hours. 50 µL of each culture was incubated in 5 
mL of LB broth without antibiotics with shaking at 200 rpm at 30⁰C until the OD600 of the culture was 
between 0.3 and 0.4. Once the subcultures reached that range, they were placed on ice. The volume of 
the subculture required to start the growth curve with an OD of 0.005 and a 2 mL total volume was 
calculated. 
Absorbance measurements were taken in duplicate of the following bacterial cultures in respective 
media: Hm21 + LB, Hm21 + 0.007 µg/mL Cp LB, Hm21 + 0.01 µg/mL Cp LB, Hm21 + 0.05 µg/mL Cp LB, 
Hm21 + 1 µg/mL Cp LB, and Hm21 + 4 µg/mL Cp LB. JG1471 was grown and measured at the same Cp 
concentrations listed for Hm21. 200 µL of each mix was added to a 48-well plate. A set of control wells 
were measured for absorbance containing media but no bacterial culture. These wells were used to 
measure background absorbance and this value was subtracted from the absorbance measurements of 
each bacterial culture in media containing the respective Cp concentration. For example, if X absorbance 
units were measured in LB with no Cp added, then X was subtracted from the average of triplicate 
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measurements of bacterial culture + LB no Cp. The plate was measured using a Biotek ® Microplate 
reader at 30⁰C over 24 hours and readings were taken every 10 minutes.   
3.5 Plasmid isolation and purification 
The strains containing plasmids p1471 and pKAS46 were streaked from frozen stocks for isolation on 4 
µg/mL Cp LB plates and 100 µg/mL Km plates respectively. JG1471 was grown at 30⁰C for 16 hours. E. 
coli + pKAS46 was grown at 37⁰C for 16 hours. Overnighters were then made with 10 mL LB and the 
required antibiotic and incubated for 16 hours at 225 rpm. Plasmid purification was performed using the 
Wizard® Plus SV Minipreps DNA Purification System (Promega, Madison, WI). To confirm isolation of the 
plasmid, purified plasmids were run on an 0.8% SeaKem® LE Agarose gel (Lonza, Hopkinton, MA) for 40 
minutes at 85V.  
3.6 Gibson Assembly and Transformation into E. coli. 
To ligate p1471 to a fragment of pKAS46, the first step of the GA was isolation of the plasmid as 
described above. Then, the 6.8kb p1471 and 2 kb pKAS46 fragments were PCR amplified. The primers in 
Table 3 were designed for a Phusion PCR reaction. All tubes included 2.5 µL of both the forward and 
reverse primer, 25 µL of Phusion master mix, the amount of plasmid DNA required for a target of 5-10 
ng in the reaction tube, and the required volume of PCR H2O for a total volume of 50 µL. For the p1471 
reaction, the annealing temperature was 65⁰C. The following cycling conditions were applied: i) 98⁰C for 
30 seconds, ii) 98⁰C for 10 seconds, 65⁰C for 30 seconds, and 72⁰C for 2 minutes, iii) Step ii repeats 30 
times, iv) 72⁰C for 10 minutes, and v) held at 10⁰C indefinitely. In the pKAS46 reaction, the annealing 
temperature of the primers is 62⁰C. The protocol requires that the reaction mix be heated at i) 98⁰C for 
30 seconds, ii) 98⁰C for 10 seconds, 62⁰C for 30 seconds, and 72⁰C for 1 minutes and 10 seconds, iii) 
repeat step ii 30 times, iv) 72⁰C for 10 minutes and v) 10⁰C indefinitely.  
The template pKAS46 plasmid was prevented from being transformed in forthcoming steps by a 
DpnI restriction digest. The pKAS46 plasmid was isolated and purified directly from bacterial cells, and is 
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methylated. DpnI is a restriction enzyme that binds and digests at G-methylated A-T-C in both the 
forward and reverse direction29. Since DpnI only digests methylated DNA, any remaining pKAS46 
template was be digested but the amplified 1.9 kb fragment remained uncut as the PCR product was not 
methylated29. 5µL of Cutsmart Buffer, 1 µL of DpnI enzyme, the volume required for 1 µg of pKAS46 and 
the volume of PCR H2O required for a 50 µL total volume were combined in a PCR tube and placed at 
37⁰C for 16 hours, 80⁰C for 20 minutes for enzyme inactivation, and then held at 10⁰C indefinitely.  
Next, the GA was performed to ligate the insert and vector fragments. A 1:1 (p1471 to pKAS46) 
GA ratio, a pUC19 positive control, and a negative control with neither p1471 or pKAS46 present were 
used. The total volume in the GA tube was 10 µL. 5 µL was made up of the GA master mix. The amount 
of p1471 should be 50 ng total. In order to have a 1:1 GA ratio, the concentration of pKAS46 DNA 
required was 0.011 pmoles, and the total amount (ng) of pKAS46 required was 29 ng. The DNA was 
added to the GA tube with the appropriate amount of dH2O for a total concentration of 10 µL. The 
negative control contained 5 µL of GA master mix and 5 µL of dH2O. The three GA reaction tubes were 
incubated for 30 minutes at 50⁰C and then placed on ice until used for transformation. 
The three GA reactions were transformed into competent DH5α-λpir E. coli Hanahan cells30. The 
transformation reactions contained the following: the 1:1 GA reaction, the GA reaction without DNA, 
and pUC19 as a positive control. The Gibson assembly was diluted by adding 30 µL of distilled water to 
the 10µL GA. Next, 2 µL of this dilution was added to a tube on ice and 50 µL of Hanahan competent 
cells were added and mixed. 1 µL of pUC19 was added to the 50 µL of competent cells as a positive 
control. The solutions were placed on ice for 30 minutes. They were heat-shocked in a 42⁰C water bath 
for 1:15 minutes, removed and placed on ice for 3 minutes. Next, 950 µL of SOC media was added to 
each tube. The samples were incubated with shaking (200 rpm) at 37⁰C for 30 minutes. 
After the transformation, the cells were plated to select for growth. The 1:1 ratio and negative 
control GA mixes were plated on LB and LB + 100 µg/mL Km for selection of transformants: a 10/90 
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cell/SOC dilution on LB and LB + 100 µg/mL Km, and 100 µL directly spread on LB and LB + Km. The 
leftover culture was centrifuged at 8000 rpm for 2 minutes, the supernatant was decanted, and the 
culture was resuspended and spread on a Km plate. The positive controls were plated on LB+ 100 µg/mL 
ampicillin (Amp) plates: 100 µL directly spread, a 10-fold dilution of 100 µL culture in 900 µL SOC (plating 
100 µL total from the mix), and a centrifuged culture as mentioned above for the Amp plates. All plates 
were incubated for 16 hours overnight at 37⁰C and growth was observed.  
3.7 Confirmatory tests 
Three colonies from the transformed pEL1 Km plate (from cells grown on the centrifuged GA 1:1 
ratio of p1471 to pKAS46 Km plates) were streaked on 100 µg/mL Km plates. The plasmid pEL1 
assembled with the Gibson assembly was then repurified from the E. coli cells and run on a gel using the 
specifications mentioned in step 3.5 above. The next steps were diagnostic tests to confirm that the 
plasmid isolated from the transformed cells was indeed pEL1. First, a diagnostic PCR was performed 
using primers designed to detect qnrS2. Six plasmid purifications total were performed from the 
subcultured isolated colonies, and they were tested with the qnrS2 primers. The sequences of the qnrS2 
forward primer is GCAAGTTCATTGAACAGGGT, and the sequence of the qnrS2 reverse primer is 
TCTAAACCGTCGAGTTCGGCG. A p1471 sample was used as the positive control for the PCR, with pKAS46 
as the negative control. The reaction tubes include 12.5 µL of Taq polymerase, 0.25 µL of both the 
forward and reverse primer, and 20-30 ng of template DNA (with PCR H2O to bring the tube volume to 
25 µL total). The PCR tubes were put in the PCR machine and were heated to 94⁰C for 2 minutes then 
94⁰C for 30 s, 50⁰C for 30 seconds, then 72⁰C for 30 seconds. The previous three steps repeated 30 
times, and then the samples were heated to 72⁰C for 10 minutes and held at 10⁰C until removed from 
the thermocycler. The PCR products were run for 45 minutes at 85 Volts on a 1.2% SeaKem® LE Agarose 
gel to visualize the bands. 
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The next diagnostic test consisted of PCR using the original primers that linearized the fragments for the 
GA (listed in Table 3). If both the p1471 and pKAS46 fragments were amplified by the GA primers, the 
identity of the isolated plasmid as pEL1 could be confirmed. The same six isolated plasmid samples used 
for the qnrS2 diagnostic PCR mentioned above were used for the GA primer PCR. The GA PCR step 
followed the same PCR instructions as were mentioned above in section 3.6. The PCR products were 
then run on a 0.8% SeaKem® LE Agarose gel for 42 minutes at 85V.  
3.8 Sanger Sequencing  
pEL1 was sequenced from the left inverted repeat region of qnrS2 through both sites joining pKAS46 and 
p1471. Based on the sequences of p1471 and pKAS46 previously determined through sequencing with 
PacBio and Illumina, eight primers were designed for every 500-600 nucleotides. The annealing 
temperature for the primers was between 55 and 65⁰C, 18-25 nucleotides long, with a 1 or 2 nucleotide 
GC clamp on the 3’ end of the primer. The first primer began 50 nucleotides upstream of the inverted 
repeat region of qnrS2 and the next primer was designed for 550 nucleotides downstream from there. 
The primers used for sequencing pEL1 are shown in Table 4. Each primer’s sequencing container 
contained 1.5 µL of 2.5x BigDye v1.1, 3 µL of 5x BigDye Buffer, 200 ng of plasmid template, and the 
amount of dH2O for a total volume of 20 µL. The primer tubes were placed in a thermocycler and went 
through these steps: i: an initial denature stage of 96⁰C for 2 minutes, a denature stage at 96⁰C for 20 
seconds, an annealing phase of 10 seconds at 50⁰C, an extension phase at 60⁰C for 4 minutes. The three 
previous steps were then repeated 32 times, and the tubes were held in the thermocycler at 12⁰C until 
removed.  
Next, 5 µL of EDTA solution at pH8 and 125 mM was added to each of the primer reactions. 70 µL of ice 
cold 95% ethanol was added to the solutions and they were mixed by pipetting. The samples 
precipitated overnight at -20⁰C. The samples were spun for 10 minutes at 4⁰C at max speed and the 
supernatant was removed. 600 µL of 75% ice-cold ethanol was added to the tubes which were briefly 
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vortexed and centrifuged at max speed for 10 minutes at 4⁰C again. The supernatant ethanol was 
decanted. This ethanol step was repeated twice more. The excess ethanol was left to evaporate off the 
tubes by leaving the lids of the MCF tubes open for 20-30 minutes. The samples were sequenced by the 
DNA Biotech facility and the returned sequences were analyzed using SnapGene.  
3.9 E-testing  
E-testing was performed to quantify whether or not the addition of pEL1 provides E. coli cells with an 
increased resistance to Cp. E-testing measures the minimum inhibitory concentration (MIC) of a certain 
bacteria. MIC is the lowest concentration of the desired antimicrobial agent that is required to prevent 
visible growth of a bacteria. First, strains are streaked for isolation on blood agar. The strains tested 
were DH5α-λ pir E. coli without pEL1 and DH5α-λ pir E. coli with pEL1 present. For the Aeromonas E-
testing, the strains tested were Hm21, Hm21+pEL1, Hm21RS, gyrA mutants of Hm21RS with and without 
pEL1, and parC mutants of Hm21RS with and without pEL1 present. The quality control (E. coli ATCC 
25922) was also streaked on blood agar. The plates were placed in the 35⁰C incubator for 18-20 hours. 4 
mL of autoclaved 0.85% NaCl was pipetted aseptically into test tubes. All of the tested strains had a 
single test tube. For each, isolated colonies were aseptically added from the blood agar plate until the 
solution matched the turbidity of the 0.5 McFarland Standard. Autoclaved cotton swabs were placed in 
the solution, allowed to sit for a minute, excess moisture was removed, and they streaked on Mueller 
Hinton agar three times. Excess moisture was absorbed by letting the plate sit for 20 minutes. Forceps 
were used to aseptically pick up the Etest® Cp strips (bioMérieux and Durham, NC), and place on the 
agar with writing face up. The plates were incubated for 18-20 hours at 35⁰C and the Etest® strip was 
read by observing the place on the strip where the apex of the zone of inhibition met the bacterial 
growth.  
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3.10 Transformation into CpS Aeromonas veronii 
Preparation of competent Aeromonas cells31:  
CpS A. veronii was inoculated in LB broth. It was incubated with shaking at 30⁰C overnight. 0.5 mL of the 
overnight culture was added to 50 mL of SOB broth in a 250 mL Erlenmeyer flask. The bacteria grew at 
30⁰C until the OD600 = 0.5. The cells were transferred to chilled centrifuge tubes. The culture was 
centrifuged for 8 minutes at 6000 rpm at 4⁰C. The supernatant was poured off without disturbing the 
culture. 1 mL of ice cold 10% glycerol was added and cells were resuspended by pipetting. 5 mL of ice 
cold 10% glycerol was added to each tube and mixed gently. The centrifugation was run for 8 minutes, 
6000 rpm at 4⁰C. The supernatant was decanted and the above steps were repeated from the 1 mL 
resuspension three more times. After the wash steps, the supernatant was removed without pellet loss, 
the remainder was transferred into MCF tubes, and centrifuged on a tabletop centrifuge for 8 minutes 
at 60000 rpm at 4⁰C. The supernatant fluid was poured and the cells were resuspended in 150 µL of ice-
cold 10% glycerol. 55 µL of the competent cells were used for each electroporation. 
Electroporation of cells:  
Electrocompetent Aeromonas cells were electroporated at 12kV/cm with 50 ng of purified pEL1 and 
incubated in SOC medium for recovery at 35⁰C for one hour with gentle shaking as previously 
described32.Transformation of Aeromonas with pMMB207 was conducted as a positive control. 10 ng 
and 50 ng of pMMB207 DNA was added. 100 µL of the electroporated solution was plated on 1 µg/mL 
chloramphenicol (Cm) plates, and 100 µL on LB agar. The rest of the solution was centrifuged for 2 
minutes at 8000 rpm at room temperature, resuspended after all but 100 µL of the supernatant fluid 
was poured off, and the cells were then resuspended and plated. 
50 ng of pEL1 was used for the transformation, and 100 µL of the solution was plated on 100 µg/mL Km 
plates, 100 µL on LB plates, and spun down and plated on 100 µg/mL Km plates as described for the 
positive control.  
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In order to explore qnrS2 and the p1471 plasmid further, 10, 50, and 100 ng of each p1471 and an IncU 
plasmid were transformed into Hm21. The p1471 transformations were spun and plated on 1 µg/mL Cp 
plates and the IncU transformations were spun and plated on 4 µg/mL Cp plates.  
The two plasmids were each included in the experiment for different reasons. The IncU plasmid also 
contains the qnrS2 gene, but is present only as a single-copy plasmid in the bacterial cell, where pEL1 
and p1471 are high copy plasmids. Observing a difference in MIC between one copy and multiple copies 
of qnrS2 could help provide more information on the gene and its mechanisms. To determine whether 
the native plasmid could be transformed using the same methods, p1471 was included in the 
transformation procedure and it was observed to see if there would be any phenotypic differences 
between the p1471 and pEL1.  
The procedure for competent Aeromonas cells and electroporation was repeated using gyrA-mutant 
Hm21RS and parC-mutant Hm21RS to transform pEL1 into the two strains. Both were taken from frozen 
stocks and streaked on 100 µg/mL streptomycin (Sm) plates. Colonies were inoculated from 
streptomycin plate into 5 mL LB broth containing 100 µg/mL Sm and the cells were made competent 
using the protocol above. When the transformed media was plated, the 100 µL direct volume to the Km 
plates was not included in order to make sure there were enough transformed colonies in the plate that 
included the results from the spun-down centrifuge step. 
No plasmid was transformed in the negative controls, and 100 µL of the solution was plated on 
100µg/mL Km plates, 1 µg/mL Cm plates, LB plates, and spun down and plated on 100 µg/mL Km agar. 
The plates were placed at 30⁰C for 16-18 hours and results were recorded. The transformed colonies 
were taken from the Km plates and streaked onto new Km plates for isolation, future overnight cultures, 
creation of frozen stock, and isolation of plasmid using the protocol in 3.5. Plasmid identity was then 
confirmed with the steps in 3.7. 
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3.11 Oxidase testing  
Oxidase testing was performed to support that the strains with pEL1 transformed were oxidase positive. 
Colonies were scraped on a sterile Kim wipe that had been saturated with the oxidase test solution 
(0.048 g of N’,N’,N’,N’-Tetramethyl-p-phenylenediamine dihydrochloride in 8 mL of nanopure water). A 
positive oxidase test result was the appearance of a blue color upon addition of the colonies to the 
saturated Kim wipe.  
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IV. Results 
4.1 Growth curve 
It may be hypothesized that the increased energy needed to replicate p1471 as a high copy plasmid 
would lead to some defect in the growth rate in LB when compared to Hm21 in the absence of 
antibiotics. The growth rates of JG1471 and CpS control A. veronii strain Hm21 during the exponential 
phase were determined in varying levels of Cp (Figure 3). In LB without Cp, Hm21 had a growth rate of 
0.046 hr-1 while JG1471 had a slower growth rate of 0.007 hr-1. Though the growth rate with just LB was 
higher for Hm21, the growth rate of JG1471 in the presence of Cp was consistently higher than that of 
Hm21, as can be seen in Table 5. At 0.05, 1, and 4 µg/ml Cp, Hm21 had a growth rate of zero. While the 
growth rate of JG1471 in LB was lower than that of Hm21 in LB, the growth yield of JG1471 was larger in 
the stationary phase, with a higher optical density based on cell growth. JG1471 had the highest growth 
yield when grown in the presence of LB + 4 µg/mL Cp. The ability of JG1471 to grow at 4 µg/mL Cp is a 
result of Cp resistance mechanisms. 
4.2 Bioinformatic Analysis of p1471 
The CpR of JG1471 is likely a result of the mutations in gyrA and parC, as well as the presence of qnrS2 in 
p1471. The CpR plasmid p1471 contains qnrS2, which may play a role in its high MIC, but qnrS2 is not the 
only gene present on the plasmid. It also contains a gene coding for the NspV endonuclease type II 
restriction enzyme that could be involved in ensuring the maintenance of the plasmid. Downstream 
from this is an nspV modification methylase gene to protect its own DNA against the cleavage action of 
the NspV restriction enzyme33. This is a common mechanism used by bacteria and archaea to disrupt the 
DNA of potential pathogens while still protecting the host DNA but it has also been proposed as a 
mechanism to ensure plasmid stability33. p1471 also contains a repB gene, which codes for a plasmid 
replication protein that may help regulate replication of the plasmid34. Another gene on p1471 is an 
addiction module antitoxin. While toxin/antitoxin systems have not been well characterized, it has been 
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hypothesized to be similar to the nspV endonuclease and methylase system, with toxic actions 
counteracted by the antitoxin encoded on its own plasmid35. The combination of the toxin/antitoxin and 
nspV restriction enzyme system could provide JG1471 with an increased protection against foreign 
microbes or pathogens. The important genetic marker for CpR on the plasmid is the aforementioned 
qnrS2. In order to study the resistance that the presence of qnrS2 provides, the p1471 plasmid was 
ligated to the pKAS46 1.99 kb fragment using the GA and transformed into CpS bacteria. 
4.3 Plasmid isolation and purification 
The 1.99kb pKAS46 fragment was chosen for several reasons. An origin of replication was included (R6K) 
to allow for replication of the plasmid after transformation into E. coli. The addition of the R6K origin of 
replication allowed for this replication in DH5α-λpir cells but shout not change replication or the copy 
number in Aeromonas as plasmids with the R6K ori are suicide vectors in Aeromonas36 . The Km-
resistance marker present in the pKAS46 fragment allowed for selection of transformed colonies after 
the GA and transformation. This extra selective marker was helpful because the Cp resistance provided 
by the presence of qnrS2 in the plasmid was not quantified, so 100 µg/mL Km plates were used to select 
for successfully transformed cells. The multiple cloning site in the pKAS46 fragment allows for future use 
of the plasmid as a shuttle vector in experiments. Transformation into Aeromonas has been problematic 
in the past, so a well-characterized shuttle vector such as pEL1 that transformed successfully would be a 
valuable tool for future use.  
In order to isolate the p1471 and pKAS46 plasmids for the GA protocol, a Wizard® Plus SV Minipreps 
DNA Purification System was used. In Figure 4, a 0.8% SeaKem® LE Agarose gel shows the successful 
isolation of the two plasmids. p1471 shows a band at 6.8 kb and pKAS46 shows a band at 5.9 kb. After 
purification of the two plasmids, the GA was performed to ligated the p1471 and pKAS46 fragments. 
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4.4 Gibson Assembly and Transformation 
In order to continue with the GA, p1471 and the 1.99kb fragment of pKAS46 were amplified by 
PCR for a linear product. In Figure 5, a 0.8% SeaKem® LE Agarose gel suggests that the PCR amplification 
was successful; both p1471 and the pKAS46 fragment show the expected band size. Figure 2 shows a 
diagram of the fragments and ligated construct of pEL1. 
After amplification of p1471 and the fragment from pKAS46, a DpnI digest was performed to 
digest the methylated template DNA from the pKAS46 PCR tube. In previous experiments without this 
DpnI step, pKAS46, rather than pEL1, was re-isolated at the end of the transformation procedure 
because the template DNA from the PCR out-competed the assembled plasmid. Figure 6 shows the 
difference between a confirmatory PCR with qnrS2 with and without the addition of the DpnI digest to 
the protocol. In A, no qnrS2 was detected from the transformed plasmid because pKAS46 was re-
purified rather than p1471. In B, a DpnI digest was performed before the GA protocol, the pKAS46 
template DNA was not transformed, and the pEL1 plasmid annealed properly. 
After the fragments annealed, the newly assembled pEL1 plasmid was transformed into Hanahan 
cells. The marker for a successful transformation was the presence of colony growth on the Km plates 
from the GA transformants. The 1:1 p1471 to pKAS46 GA ratio provided 6 distinct colonies on the 100 
µg/mL Km plate from the centrifuged and concentrated cells. Of these six distinct colonies, three were 
streaked on Km plates for isolation, and confirmatory assays were performed to make sure that the 
transformation products did contain pEL1. 
4.5 pEL1 confirmatory assays 
In order to confirm that the transformed colonies from the Km plate actually received their Km 
resistance from pEL1 rather than pKAS46, several confirmatory assays were performed. First was the 
PCR reaction with qnrS2 primers mentioned in part 4.2. The gene qnrS2 was part of the pEL1 assembled 
construct due to the addition of the p1471 fragment to the assembly. Because the qnrS2 primers did 
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show amplification of the qnrS2 gene from the plasmid in part B of figure 5, there was evidence that 
p1471 was present in the final construct.  
The next confirmatory assay was a PCR using the original primers designed to linearize the 
fragments for the GA. If the fragments assembled correctly to make pEL1, both p1471 and the 1.99kb 
pKAS46 fragment should have been amplified when pEL1 was tested. The confirmatory PCR with the GA 
primers was a success. Samples B-F in Figure 7 show a band near 6.8kb, exactly where the p1471 linear 
fragment is expected to be. Sample A seems to have some form of truncated version of the fragment, so 
this particular pair of the E. coli and plasmid were excluded from future experiments. Samples A-F all 
show the expected 2kb band of the amplified pKAS46 fragment. The diagnostic assays confirmed the 
identity of the transformed plasmid to be pEL1 and frozen stocks were made of E. coli with the plasmid 
for use in future experiments.   
4.6 Sanger Sequencing 
After confirmation of successful p1471 and pKAS46 assembly, sequencing confirmed that no 
mutations or ligation mistakes had occurred during the GA process. If a mutation had occurred in qnrS2 
or part of the pKAS46 fragment, future tests could be impacted. Eight primers were designed to amplify 
the assembled region. Because qnrS2 is the gene of interest in the p1471 plasmid, primers were 
designed to begin at the left of the inverted repeat region of the gene and continue through qnrS2, its 
right inverted repeat region, and pass all the way through the pKAS46 fragment. The eighth primer did 
not bind or amplify the DNA, but primers 1-7 did sequence the desired region, as seen in Figure 8. The 
seven primers sequenced the pEL1 area of interest and showed definitively that there were no 
mutations in the sequence of the plasmid as compared to the original components. The plasmid pEL1 
was successfully assembled and transformed into E. coli without mutations. 
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4.7 E testing of E. coli + pEL1 
The presence of the pEL1 plasmid allowed for a test to determine the phenotypic changes 
associated with the presence of the plasmid in E. coli. In order to determine what level of CpR was 
conferred to the susceptible strain upon addition of the pEL1 plasmid, E-testing was performed to 
determine the MIC of Cp for the bacteria. ATCC25922 E. coli was used as a quality control for the E-
testing and showed an MIC within the expected bounds.  
DH5α-λ pir E. coli showed a marked increase in MIC upon addition of pEL1 (Table 6). The MIC 
increased from 0.032 µg/mL without plasmid to 0.25 µg/mL when pEL1 was present in the bacteria. 
Because this E. coli strain does not have any of the chromosomal mutations that lead to CpR, the change 
in resistance of this strain is likely due to pEL1 and the presence of the gene qnrS2.   
4.8 Transformation of pEL1 into A. veronii 
In order to study the effect of the presence of qnrS2 in CpS Aeromonas, pEL1 was transformed into 
A. veronii. After transformation of five reactions containing 50 ng of pEL1 added to 55 µL competent A. 
veronii, a total of 13 isolated colonies grew on the spun-down plates across the five reactants. Five of 
the colonies were streaked for isolation, inoculated in overnighter cultures, and saved as frozen stocks. 
The positive controls showed growth of many colonies containing pMMB207 growing on 1 µg/mL Cm 
plates, and the negative control showed a lack of growth on all plates except LB. p1471 and an IncU 
plasmid containing qnrS2 were also transformed in Hm21 but neither yielded any transformants on the 
selective Cp media. pEL1 was purified from frozen stocks #1 and #2 of Hm21 pEL1. From there, qnrS2 
and GA primers were used to confirm the identity of the transformed plasmid as pEL1. The presence of 
PCR products using the qnrS2 and GA primers (Fig. 9), confirms that pEL1 was present in Hm21 + pEL1.  
pEL1 was transformed into gyrA and parC mutants of Hm21RS A. veronii. gyrA and parC Hm21RS 
mutants are both hypothesized to have an increased CpR due to the genomic mutation, so 
transformation of pEL1 to each allowed further exploration of the MIC conferred by the different 
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resistance factors. There was a lawn of growth on the 100 µg/mL Km plates (transformed with 10, 50, 
and 100 ng of pEL1). Fig. 10 shows the presence of qnrS2 in all but two of the Hm21RS gyrA and Hm21RS 
parC strains after colony PCR of the transformed cells. Oxidase tests were performed on all transformed 
colonies to support that Aeromonas was the recipient bacteria. The oxidase tests were positive as 
expected for Aeromonas. The next step was to observe the MIC change in Aeromonas as a result of 
pEL1. 
4.8 E-Test of Aeromonas + pEL1 
Transformation of pEL1 into strains of CpS A. veronii was hypothesized to lead to an increased 
MIC for each strain as a result of the presence of qnrS2. After transformation of the qnrS2 containing 
pEL1 plasmid into the CpS A. veronii bacteria in the first trial, the MIC increased to 6 µg/mL from its 
starting point of 0.002 µg/mL. The addition of the pEL1 plasmid led to a dramatic increase in the MIC 
and changed a CpS strain of Aeromonas to a CpR one. Table 7 shows the MIC results for the 1st and 2nd E-
test trials. 
After the second trial of E-testing, the MIC results of Hm21 A. veronii + pEL1 showed a different 
MIC value; instead of the 6 µg/mL MIC determined in trial 1, the MIC was 0.032 µg/mL. While there is a 
large difference between the MIC values from the two trials, both values support that addition of qnrS2 
to a CpS strain of Aeromonas increases the MIC dramatically. The gyrA Hm21RS mutant showed a 
phenotype MIC of 0.094 µg/mL before transformation of the plasmid due to its genomic mutation, and 
0.125 µg/mL after addition of pEL1. The parC Hm21RS mutant did not contain inherent resistance as a 
result of the genomic mutation, but increased from 0.003 µg/mL to 0.032 µg/mL after transformation of 
pEL1, just as the second Hm21 + pEL1 trial did.  
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V. Discussion  
Bacteria with elevated resistance to Cp are increasingly being isolated in hospitals, and a greater 
understanding of the factors which contribute to Cp resistance and how they are acquired is needed to 
combat this growing problem. Aeromonas species can be found in water sources such as hospital 
wastewater, drinking water in cities, and natural aquatic environments in addition to the leech gut37. It 
has been suggested that horizontal transfer in such settings plays a role in the acquisition of antibiotic 
resistance determinants later found in clinical and environmental isolates37. This factor combined with 
the widespread overuse of antibiotics leads to a buildup of Cp in the environment and selection of 
resistant bacteria37,38. Selection for resistance factors due to the presence of low-level Cp in the 
environment may be the mechanism by which leech symbionts acquire resistance factors. JG1471 may 
have adapted to grow slightly better in the presence of Cp if the bactericidal agent is found, as has been 
suggested, in many water and waste sources3>. The high Cp resistance found in JG1471 is likely a result 
of gyrA and parC mutations in the genome and the qnrS2 gene present on the p1471 plasmid.  
The gene qnrS2 is a resistance factor that has not been well characterized but is observed in 
Aeromonas strains isolated from the environment and clinical sources24,40. This resistance gene has been 
discovered on IncU and IncQ-like plasmids that take part in conjugative transfer and is a likely 
mechanism by which qnrS2 and other qnr genes have disseminated into environmental isolates24,41. In 
order to study the qnrS2 gene present in p1471, p1471 was ligated the 2kb fragment of pKAS46 to form 
the pEL1 plasmid. The addition of the R6K origin of replication allowed the pEL1 plasmid to replicate in 
DH5α-λpir E. coli but did not affect the copy number of pEL1 in Aeromonas because of the role of 
pKAS46 as a suicide vector in Aeromonas36.  
When qnrS2 was transformed into the CpS DH5α-λ pir E. coli cells, there was an MIC increase 
from 0.032 µg/mL to 0.25 µg/mL. These results were consistent with those in previous literature about 
qnrS2 addition to E. coli (Table 2). When plasmids containing qnrS2 were conjugated from Aeromonas 
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species into various strains of E. coli in other studies, the MIC values were similar. One E. coli 
transconjugant experienced a change from 0.015 µg/mL to 0.25 µg/mL upon addition of the gene42. Two 
separate qnrS2 isolated plasmids conferred an increase from <0.01 µg/mL to 0.25 µg/mL in both E. coli 
TOP10 transconjugants24. One qnrS2 plasmid found in a clinical sample changed the MIC of E. coli from 
0.023 µg/mL to 0.5 µg/mL, while another environmental qnrS2 plasmid changed the E. coli MIC from 
<0.02 µg/mL to 0.15 µg/mL4>,43. While not all the MIC values for E. coli + qnrS2 are exactly the same, all 
are low when compared to the 4 µg/mL clinical cut off for resistance. This increase in MIC in E. coli 
continues to support the hypothesis that the presence of qnrS2 increases CpR, but it does not suggest if 
MIC values are comparable when pEL1 is present in a CpS Aeromonas strain 
Because the R6K origin of replication does not allow for replication in Aeromonas strains, the 
origin of replication coded by the p1471 plasmid is used, which suggests that the copy number of pEL1 
in the A. veronii recipient strain is comparable to the copy number from its original host, JG1471. The 
original plasmid p1471 is a very high copy plasmid in A. hydrophila. The successful assembly and 
transformation of pEL1 into E. coli and A. veronii provided an opportunity to evaluate the level of Cp 
resistance conferred by pEL1 to both bacteria, as determined by E-testing. While addition of pEL1 to E. 
coli (DH5α λ-pir) caused a ~8 fold increase in the observed MIC (from 0.032 µg/mL to 0.25 µg/mL), the 
transformation of pEL1 into a CpS A. veronii led to an unexpected 10.5 to 3,000 fold MIC increase (0.002 
µg/mL to 0.032 and 6 µg/mL in two independent experiments). Although not determined, it is likely that 
qnrS2 is expressed in the recipient strains and is responsible for the observed MIC increase, though the 
exact mechanism of qnrS2 is unknown. High copy levels of qnrS2 present in the cell may lead to a higher 
level of CpR. While qnrS2 gene conjugation in previous studies has shown an MIC increase in E. coli, as 
seen in Table 2, the resultant bacteria were still CpS with MIC values closer to 0.25 or 1. In cases where 
the qnrS2 gene was present in the bacteria without other resistance factors, both Aeromonas and 
Salmonella strains isolated from the environment and clinical samples showed a CpS phenotype4>,44. The 
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addition of the pEL1 plasmid to Hm21 A. veronii led to a dramatic increase in the MIC and changed a CpS 
strain of Aeromonas to a CpR one. Further study of how this plasmid increases the MIC of Cp in 
Aeromonas strains when genomic substitutions in the QRDR are already present will help determine 
how various combinations of these genetic determinants alter overall CpR.  
The addition of the qnrS2 gene to gyrA and parC Hm21RS mutants also showed an increase in 
MIC in Table 7 after E-testing. The gyrA mutant had an MIC of 0.94 µg/mL before transformation, likely 
due solely to the mutation in the QRDR of gyrA. After transformation with pEL1, this MIC increased to 
0.125 µg/mL. This showed an MIC increase that was likely based on the combination of the gyrA 
genomic mutation in the QRDR and the plasmid-mediated qnrS2 CpR gene. The parC Hm21RS mutant 
itself did not show any inherent CpR despite its genomic mutation, with an MIC of 0.003 µg/mL. But after 
addition of pEL1 and qnrS2, the MIC of the parC Hm21RS mutant increased to 0.032 µg/mL. A second 
trial of Hm21 + pEL1 led to an MIC increase of 0.003 µg/mL to 0.032 µg/mL. This ~10.5-fold increase in 
MIC is in stark contrast to the 3,000-fold MIC increase shown in the first E-test of CpS Hm21 + pEL1. 
Future research will explore the reason for the difference in MIC measured from the same transformed 
bacteria. It is possible that the copy number of the pEL1 plasmid is subject to the stage of cell growth; 
determination of plasmid copy number in the literature has been shown to be variable based on the 
stage of growth of some bacteria, whether they are in lag, exponential growth, or the stationary 
period45. It is possible that there was a lower copy number of pEL1 due to a change in bacterial growth 
that led to a decrease in MIC after the second trial of E-testing. The next steps will be E-testing of the 
Hm21 + pEL1 bacteria after being grown to different growth points to explore whether this results in a 
change in MIC that could account for the observed discrepancy. While the MIC values are different 
between the two trials of CpS Hm21 pEL1, the MIC of every strain tested was increased after 
transformation with pEL1. It is likely that the addition of qnrS2 was responsible for the increase in MIC 
observed in the transformed strains.  
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Future research will focus on further understanding the role qnrS2 has in Cp resistance. Because 
pEL1 is a high copy plasmid in A. veronii, it is likely that increased copies of qnrS2 lead to the 6 µg/mL 
MIC observed. In order to study this hypothesis, a conjugative transfer will take place with an IncU 
plasmid, previously purified from a CpR Aeromonas leech symbiont, that contains a copy of the qnrS2 
gene. IncU is a single-copy plasmid, which means that qnrS2 would only be present as a single copy. It is 
expected that with this single copy of qnrS2 in the susceptible strain, the MIC will be lower than that 
determined after transformation of pEL1 with its likely high copy number. Further research will be 
performed to determine the specific copy number of the plasmid in each host strain so that exact 
comparisons can be made. Efforts will also continue to transform the native plasmid, p1471, into the CpS 
A. veronii strain to determine whether the addition of the 2kb pKAS46 fragment to the p1471 plasmid 
caused any phenotypic differences in MIC. 
One area of future study will be determining if growth defects are caused by the presence of 
various CpR determinants such as genomic mutations in the QRDR or plasmid-mediated factors like 
qnrS2. This will be accomplished by performing growth curves of A. veronii strains with and without the 
resistance factors to compare rates. The growth rate of CpR JG1471 was lower than that of CpS Hm21 in 
LB without Cp (table 5), but JG1471 with and without Cp showed a higher growth yield. One hypothesis 
is that the strains with the highest CpR will have a decreased growth rate like JG1471 because the cell is 
expending so much energy on producing compounds to resist Cp-mediated cell death. While the 
research of levels of CpR and their effects are clinically relevant, they are not the only applications of 
JG1471 and qnrS2.  
The MCS of pEL1 provides the option of its use as a shuttle vector for future studies in 
Aeromonas. A shuttle vector is a valuable biological tool that allows for addition of a gene of interest or 
DNA recombination46. Shuttle vectors are widely used in the biological sciences, with uses including 
genetic engineering and gene cloning in yeast and bacteria47. These tools are often used to express a 
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protein of interest in a bacteria or host that was not native to it and observe the phenotypic changes47. 
Since pEL1 is transformable into A. veronii, this plasmid may be used to express other genes or factors of 
interest using the MCS. There is some evidence that, after a gene deletion, complementation via 
plasmid may produce unstable results or false negatives due to plasmid instability or the copy number 
of the plasmid in the cell48. The potentially variable copy number of pEL1 due to the presence of p1471 
in Aeromonas cells could be a factor in effectiveness of this plasmid as a shuttle vector.  
If the shuttle vector is successful, however, the MCS could be used to insert other resistance 
factors into the plasmid and study their effects. Addition of a qepA or oqxAB gene that codes for an 
efflux pump and the subsequent change in resistance could provide an interesting future direction, 
especially if the qnrS2 gene is removed from the plasmid to study the effect of the efflux pumps without 
outside resistance factors. New CpR factors are continually being discovered due to increasing CpR in 
Aeromonas and other bacteria, and this field of study will likely continue to expand and increase in 
importance as bacterial antibiotic resistance becomes more prevalent. 
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VI. Conclusion 
The antibiotic resistance plasmid pEL1 was assembled correctly using a Gibson Assembly; confirmatory 
PCRs and Sanger sequencing confirmed a successful assembly and a complete sequence match to what 
was expected. This pEL1 plasmid could prove a valuable tool as an Aeromonas shuttle vector in future 
research. The presence of the gene qnrS2 is an important resistance factor of pEL1. The presence of 
qnrS2 provides a significant increase in MIC in susceptible strains. In E. coli, the presence of the gene 
brought the MIC from 0.016 µg/mL to 0.25 µg/mL. In CpS A. veronii, the MIC changed from 0.002 µg/mL 
in the susceptible strain to 6 µg/mL in trial 1 and 0.003 µg/mL to 0.032 µg/mL upon addition of the 
plasmid in trial 2. qnrS2 can also combine with genomic resistance factors to increase MIC. The gyrA 
Hm21RS mutant had an inherent MIC of 0.094 µg/mL due to the mutation in the QRDR and increased to 
0.125 µg/mL in the presence of qnrS2. The MIC differences shown in trial 1 and trial 2 may be a result of 
the copy number of pEL1 varying depending on cell growth stages and leading to a range of CpR 
phenotypes due to the different number of copies of the qnrS2 gene.  
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VII. Figures 
Table 2: Examples of qnrS2 and its effect on the MIC of different bacteria in the literature 
 
Reference Year
Gene 
present
Increase in 
MIC of Cp Chromosomal mutations Bacteria Plasmid Type of Isolate
Mobilizable IncQ-Related Plasmid Carrying a New Quinolone Resistance 
Gene, qnrS2, Isolated from the Bacterial Community of a Wastewater 
Treatment Plant 2006 qnrS2 Not specified N/A
Activated sludge 
bacteria
pGNB2 
(IncQ 
type) Environmental
qnrS2
from <0.02 
µg/mL to 0.15 
µg/mL N/A E. coli KAM3
pGNB2 
(IncQ 
type)
Plasmid-mediated QnrS2 determinant from a clinical Aeromonas veronii 
isolate 2008 qnrS2 8 µg/mL gyrA and parC A. veronii pA272 Clinical
qnrs2
from 0.023 
µg/mL to 0.5 
µg/mL none
E. coli 
transconjugant pA272
Unexpected occurrence of plasmid-mediated quinolone resistance 
determinants in environmental Aeromonas spp. 2008 qnrS2 4 µg/mL
one amino acid substitution 
in Ser83Ile in GyrA A. punctata
p37 (IncU 
type) Environmental
qnrS2
from <0.01 
µg/mL to 0.25 
µg/mL N/A
E. coli TOP10 
transconjugant
p37 (IncU 
type)
qnrS2 >32 µg/mL
two amino acid substitutions 
in Ser83Ile in GyrA and 
Ser80Ile in ParC A. media
p32 (IncU 
type) Environmental
qnrS2
from <0.01 
µg/mL to 0.25 
µg/mL N/A
E. coli TOP10 
transconjugant
p32 (IncU 
type)
Plasmid-mediated quinolone resistance in
Aeromonas allosaccharophila recovered from a Swiss lake 2008 qnrS2 0.12 µg/mL none in QRDR
A. 
allosaccharophila
p34 (IncU 
type) Environmental
qnrS2
from <0.01 
µg/mL to 0.25 
µg/mL N/A
E. coli TOP10 
transconjugant
p34 (IncU 
type)
Coprevalence of plasmid-mediated quinolone resistance determinants 
QepA, Qnr, and AAC(60 )-Ib-cr among 16S rRNA methylase RmtB-
producing Escherichia coli isolates from pigs 2008 qnrS2 not specified N/A
rmtB-positive E. 
coli
plasmid 
type not 
specified Veterinary
qnrS2
from 0.015 
µg/mL to 0.06 
µg/mL N/A
rmtB- positive E. 
coli 
transconjugant
plasmid 
type not 
specified
Plasmid-Mediated Quinolone Resistance in Salmonella Isolated from 
Patients with Overseas Travelers' Diarrhea in Japan 2009 qnrS2
0.5-1 µg/mL (2 
samples) none
Salmonella 
Braenderup
plasmid 
type not 
specified Clinical
qnrS2 0.5 µg/mL none
Salmonella 
Agona
plasmid 
type not 
specified
qnrS2 0.5 µg/mL none
Salmonella 
Alachua
plasmid 
type not 
specified
Plasmid-mediated QnrS2 determinant in an Aeromonas caviae isolate 
recovered from a patient with diarrhoea 2010 qnrS2 not specified not specified A. caviae
plasmid 
type not 
specified Clinical
qnrS2
0.75 µg/mL to 
1.5 µg/mL not specified transconjugant
plasmid 
type not 
specified
First description of the qnrS-like (qnrS5) gene and analysis of quinolone 
resistance-determining regions in motile Aeromonas spp. from diseased 
fish and water. 2012 qnrS2 16 µg/mL
amino acid substitutions in 
gyrA  and parC A. sobria
plasmid 
type not 
specified Diseased Fish
qnrS2 256 µg/mL
amino acid substitutions in 
gyrA  and parC A. hydrophila
plasmid 
type not 
specified Diseased Fish
qnrS2 4 µg/mL
amino acid substitutions in 
gyrA  and parC A. hydrophila
plasmid 
type not 
specified Diseased Fish
qnrS2 0.012 µg/mL none A. hydrophila
plasmid 
type not 
specified Diseased Fish
Ornamental fish as a source of plasmid-mediated quinolone resistance 
genes and antibiotic resistance plasmids 2014 qnrS2 8 µg/mL unknown A. hydrophila
plasmid 
type not 
specified Koi Carp
qnrS2 4 µg/mL unknown A. hyrdophila
plasmid 
type not 
specified Koi Carp
Prevalence and characterisation of quinolone resistance mechanisms in 
Salmonella spp. 2014 qnrS2 2 µg/mL gyrA substitution
Salmonella 
enteritidis
plasmid 
type not 
specified
Animals, food, 
and feed
Quinolone resistant Aeromonas spp. as carriers and potential tracers of 
acquired antibiotic resistance in hospital and municipal wastewater 2016 qnrS2
from 0.015 
µg/mL to 0.25 
µg/mL No
Escherichia coli 
transconjugant IncU
Aeromonas 
donor from 
clinical setting
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Figure 1: After primers are designed to overlap each fragment, the GA assembles the DNA. The 5’ ends 
are chewed back by exonuclease, DNA polymerase extends the 3’ ends of the DNA after it has annealed, 
and DNA ligase seals the nicks in DNA for a fully assembled plasmid49.  
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Table 3: The primers designed using SnapGene to linearize the p1471 plasmid and the 2kb fragment of 
pKAS46 and allow ligation during the Gibson Assembly 
Plasmid Direction Primer sequence
p1471 Forward CCCAAGAGGAACAAATCGCTC
p1471 Reverse GGGGCAACCATAAAAACAGC
pKAS46 Forward GCTGTTTTTATGGTTGCCCCgagcgtgacaatcacgaaac
pKAS46 Reverse AGCGATTTGTTCCTCTTGGGggtgttgctgactcataccag
 
Figure 2: The addition of 1.9 
kb pKAS46 fragment 
containing Km resistance 
gene, R6K origin of 
replication, and Multiple 
Cloning Sites to p1471 using 
the Gibson Assembly. A is 
the p1471 plasmid. B is the 
pKAS46 plasmid with red to 
highlight the desired 
fragment. C is the pEL1 
assembled plasmid 
A B 
C 
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Table 4: The primers designed using SnapGene to sequence the area of interest in the pEL1 plasmid. 
Primer E1 begins on the left of the inverted repeat region of qnrS2, and Primer 7 ends just after the 
ligation site between pKAS46 and pEL1. The entire qnrS2 gene and pKAS46 fragment are sequenced.  
 
 
Figure 3: Increased Cp leads to growth defect in Hm21, which is CpS . The presence of p1471 may lead to 
a growth defect in LB, but provides a growth advantage in JG1471 when  4 µg/mL Cp is present in the LB 
growth medium. 
 
Primer Name 5'-3' orientation Annealed correctly?
E1 CGTTTCGACACACAAGGCAG Yes
E2 TGGCAGCGATCAGAGTACAC Yes
E3 TTCCAACAATGCCAGCTTGC Yes
E4 AAACGTGTTTGAATGGGGCC Yes
E5 TCACGTACTAAGCTCTCATGTTTG Yes
E6 GTAATACAAGGGGTGTTATGAGCC Yes
E7 GCTTTTGCCATTCTCACCGG Yes
E8 CCCCAAGAGGAACAAATCGC No sequence
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Table 5: The specific growth rates for the Hm21 and JG1471 growth curves in LB + Cp 
 
 
 
 
 
 
 
 
 
Figure 4: The 6.8kb p1471 and 5.9kb pKAS46 were both successfully isolated by using the Promega 
Wizard miniprep kit. 
 
 
 
 
 
 
 
 
 
LB
LB+0.007 
µg/mL 
Cp
LB + 0.01 
µg/mL 
Cp
LB + 0.05 
µg/mL 
Cp
LB + 1 
µg/mL 
Cp
LB + 4 
µg/mL 
Cp
Hm21 growth rate 
(hr^-1) 0.046 0.027 0.034 0 0 0
JG1471 growth rate 
(hr^-1) 0.007 0.04 0.044 0.042 0.032 0.03
 
 
Figure 5: The linear fragments amplified by Gibson Assembly primers for p1471 and pKAS46: p1471 is 
a linear 6.8 kb, while pKAS46 primers solely amplified a 1.99kb fragment containing the R6K, KmR, 
and MCS. 
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Figure 6: The importance of the DpnI digest to prevent transformation of template plasmids such as 
pKAS46. A shows the ultimate results of the transformation and plasmid purification if the DpnI digest 
does not cut up the methylated DNA. B shows the confirmatory testing of qnrS2 PCR when the DpnI 
digest is performed to digest pKAS46. Without the DpnI digest, pEL1 was not successfully transformed 
because it was out-competed by the template pKAS46 used for PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: In A, the transformed and purified plasmid is tested using PCR using the original p1471 GA 
primers. Isolated plasmids B-F all show the expected 6.8kb band for p1471In B, the plasmids are tested 
using PCR using the pKAS46 GA primers to produce a 2kb fragment. Samples A-F all show a band at the 
2kb length where the samples should be. In samples B-F, both fragments were observed after 
purification form the transformed plasmids. 
 
 
A 
B 
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Figure 8: Seven primers designed to amplify the area of ligation of the pEL1 plasmid showed successful 
assembly of the plasmids. No point mutations or changes of any kind were found in the sequence.  
 
Table 6: MIC results from transformation of pEL1 into DH5αλpir E. coli cells. 
 
 
 
 
 
Figure 9: A shows the results of a PCR using qnrS2  
primers. It confirms that the isolated plasmids contain  
qnrS2. Figure B shows the results of a PCR using the  
GA primers, with the p1471 fragment above and the  
pKAS46 fragment below. pEL1 #2A was used in further  
transformation into the mutant strains of A. veronii.  
 
 
 
 
 
 
 
 
Strain plasmid MIC (µg/mL)
E. coli none 0.032
E. coli pEL1 0.25
E. coli pEL1 0.25
 
 
A 
B 
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Figure 10: qnrS2 colony PCR of gyrA and parC Hm21RS mutants after transformation of the pEL1 
plasmid. Moving forward, gyrA mutant #1 and #2 were used, as were parC mutants #1 and #2 because 
they both had confirmed pEL1 presence using qnrS2 PCR. 
 
 
 
Table 7: MIC values determined with and without the presence of pEL1 in recipient Aeromonas strains 
  
MIC (µg/mL)
Strain Plasmid Trial 1 Trial 2
Hm21 none 0.002 0.003
Hm21 pEL1 6 0.032
Hm21RS none N/A 0.003
gyrA  mutant 
Hm21RS none N/A 0.094
gyrA mutant 
Hm21RS pEL1 N/A 0.125
parC mutant 
Hm21RS none N/A 0.003
parC mutant 
Hm21RS pEL1 N/A 0.032
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